导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.02% | 1410/4773 |
| 近一周 | -0.16% | 1291/5467 |
| 近一月 | -3.99% | 1468/5421 |
| 近一季 | -9.11% | 2915/5238 |
| 近半年 | -2.57% | 2362/4931 |
| 近一年 | 5.55% | 1511/4400 |
| 近两年 | 95.26% | 661/2954 |
| 近三年 | 47.56% | 599/2253 |
| 成立以来 | 103.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.50% 1256/4961 |
13.72% 1960/5312 |
- - |
- - |
| 2025 | 33.78% 1097/4813 |
6.00% 696/3635 |
4.66% 718/4076 |
17.82% 2426/4524 |
2.35% 984/4813 |
| 2024 | 6.68% 1732/3463 |
-6.74% 2080/2808 |
-9.49% 2368/3014 |
15.51% 1698/3129 |
9.42% 328/3463 |
| 2023 | -6.38% 837/2656 |
7.01% 617/2280 |
-5.85% 1547/2385 |
-5.51% 1330/2515 |
-1.66% 354/2655 |
| 2022 | -24.98% 1277/2207 |
-18.44% 1338/1919 |
7.90% 416/2016 |
-15.61% 1320/2113 |
1.01% 1409/2208 |
| 2021 | 11.67% 398/1822 |
-4.85% 890/1255 |
11.47% 373/1330 |
-1.85% 545/1466 |
7.26% 186/1822 |
| 2020 | 38.51% 356/1250 |
-2.54% 267/1028 |
22.21% 216/1067 |
8.35% 721/1164 |
7.33% 717/1184 |
| 2019 | 37.21% 340/1092 |
34.88% 103/754 |
-10.53% 741/804 |
3.71% 235/850 |
9.63% 216/918 |
| 2018 | -36.04% 585/834 |
- - |
- - |
- - |
-15.48% 607/691 |
| 2017 | 6.89% 326/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.89% 427/605 |
- - |
- - |
- - |
- - |
| 2015 | 57.85% 8/575 |
- - |
- - |
- - |
- - |
| 2014 | 15.68% 197/237 |
- - |
- - |
- - |
- - |
| 2013 | 23.14% 12/186 |
- - |
- - |
- - |
- - |
| 2012 | -2.96% 135/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 广发国证2000ETF VS. 长安沪深300非周期A(740101) |